Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
Cella, David; Grünwald, Viktor; Nathan, Paul; Doan, Justin; Dastani, Homa; Taylor, Fiona; Bennett, Bryan; DeRosa, Michael; Berry, Scott; Broglio, Kristine; Berghorn, Elmer; Motzer, Robert J.
; 17(7): 994-1003, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-27283863
Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study.
Advances in treatment of metastatic renal cell carcinoma.
Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
Nivolumab in the treatment of advanced renal cell carcinoma.
Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma.
The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis.
Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study.